Patient-reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial.
Akira YokomizoHirofumi KogaKazuto ItoYutaka TakezawaMotokiyo KomiyamaKazuo NishimuraJunji YoneseKatsuyoshi HashineNaoya MasumoriGaku AraiShiro SaitoMitsuru ShinoharaNobuaki ShimizuAtsushi YamauchiTakefumi SatohTatsuo TochigiMikio KobayashiHiroyuki FujimotoKen-Ichi KakimotoIwao FukuiTaiji TsukamotoMiwako NozakiKatsuyuki KarasawaMasaru HasumiMikinobu OhtaniHiromichi IshiyamaMasaaki KuwaharaMasaoki HaradaYasuo OhashiToshihiko KotakeTadao KakizoeKazuhiro SuzukiSeiji NaitoHidetoshi Yamanakanull nullPublished in: Cancer medicine (2021)
The PRO was significantly favorable in IADT on FACT-P total score at 20 M and 38 M, PWB and functional scores at 38 M.
Keyphrases
- phase iii
- patient reported outcomes
- prostate cancer
- open label
- clinical trial
- phase ii
- early stage
- double blind
- rectal cancer
- study protocol
- placebo controlled
- randomized controlled trial
- squamous cell carcinoma
- stem cells
- lymph node
- locally advanced
- high intensity
- radiation therapy
- smoking cessation
- replacement therapy